RT Journal Article
SR Electronic
T1 Automated detection of speech timing alterations in autopsy-confirmed non-fluent/agrammatic variant primary progressive aphasia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.21.22271228
DO 10.1101/2022.02.21.22271228
A1 García, Adolfo M.
A1 Welch, Ariane E.
A1 Mandelli, Maria Luisa
A1 Henry, Maya L.
A1 Lukic, Sladjana
A1 Torres-Prioris, María José
A1 Deleon, Jessica
A1 Ratnasiri, Buddhika M.
A1 Lorca Puls, Diego L.
A1 Miller, Bruce L.
A1 Seeley, William W.
A1 Vogel, Adam P.
A1 Gorno-Tempini, Maria Luisa
YR 2022
UL http://medrxiv.org/content/early/2022/02/22/2022.02.21.22271228.abstract
AB Background and Objectives Motor speech function, including speech timing, is a key domain for diagnosing non-fluent/agrammatic variant primary progressive aphasia (nfvPPA). Yet, standard assessments employ subjective, specialist-dependent evaluations, undermining reliability and scalability. Moreover, few studies have examined relevant anatomo-clinical alterations in patients with pathologically-confirmed diagnoses. This study overcomes such caveats via automated speech timing analyses in a unique cohort of autopsy-proven cases.Methods In a cross-sectional study, we administered an overt reading task and quantified articulation rate, mean syllable and pause duration, and syllable and pause duration variability. Neuroanatomical disruptions were assessed via cortical thickness and white matter atrophy analysis.Results We evaluated 22 persons with nfvPPA (mean age: 67.3; 13 females) and confirmed underlying four-repeat tauopathy, 15 persons with semantic variant primary progressive aphasia (svPPA; mean age: 66.5; 8 females), and 10 healthy controls (HCs; 70 years; 5 females). All five speech timing measures revealed alterations in persons with nfvPPA relative to both the HC and svPPA groups, controlling for dementia severity. Articulation rate robustly discriminated individuals with nfvPPA from HCs (AUC = .95), outperforming specialist-dependent perceptual measures of dysarthria and apraxia of speech severity. Patients with nfvPPA exhibited structural abnormalities in left precentral and middle frontal as well as bilateral superior frontal regions, including their underlying white matter. Articulation rate was associated with atrophy of the left pars opercularis and supplementary/presupplementary motor areas. Secondary analyses showed that, controlling for dementia severity, all measures yielded greater deficits in patients with nfvPPA and corticobasal degeneration (nfvPPA-CBD, n = 12) than in those with progressive supranuclear palsy pathology (nfvPPA-PSP, n = 10). Articulation rate robustly discriminated between individuals in each subgroup (AUC = .82). More widespread cortical thinning was observed for the nfvPPA-CBD than the nfvPPA-PSP group across frontal regions.Discussion Automated speech timing analyses can capture specific markers of nfvPPA while potentially discriminating between patients with different tauopathies. Thanks to its objectivity and scalability, this approach could support standard speech assessments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA. M. Garcia is an Atlantic Fellow at the Global Brain Health Institute (GBHI) and is supported with funding from GBHI, Alzheimer's Association, and Alzheimer's Society (GBHI ALZ UK-22-865742); as well as CONICET; ANID (FONDECYT Regular 1210176); and Programa Interdisciplinario de Investigacion Experimental en Comunicacion y Cognicion (PIIECC), Facultad de Humanidades, USACH. A. E. Welch reports no disclosures relevant to the manuscript. M. L. Mandelli reports no disclosures relevant to the manuscript. M. L. Henry is supported by the National Institutes of Health (NIDCD R01DC016291). S. Lukic reports no disclosures relevant to the manuscript. M. J. Torres-Prioris has been funded by a postdoctoral fellowship under the program Plan Andaluz de Investigacion, Desarrollo e Innovacion (PAIDI 2020) (DOC_00421). J. Deleon is supported by the National Institutes of Health (NIDCD K23 DC018021). B. M. Ratnasiri reports no disclosures relevant to the manuscript. D. L. Lorca-Puls is supported by a postdoctoral fellowship from the National Agency for Research and Development (ANID BECAS-CHILE 74200073). B. L. Miller reports no disclosures relevant to the manuscript. W. W. Seeley reports no disclosures relevant to the manuscript. A. P. Vogel is Chief Science Officer of Redenlab Inc. The Memory and Aging Center is also supported by the Larry L. Hillblom Foundation; John Douglas French Alzheimer's Foundation; Koret Family Foundation; Consortium for Frontotemporal Dementia Research; and McBean Family Foundation. Maria Luisa Gorno Tempini is supported by grants from the National Institutes of Health (NINDS R01 NS050915, NIDCD K24 DC015544; NIA U01 AG052943).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants or their caregivers provided written informed consent before inclusion, in accordance with the Declaration of Helsinki. The UCSF Human Research and Protection Program Institutional Review Board approved the three studies participants consented to (10-03946, 10-00619, 12-10512).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublic archiving of anonymized data is not contemplated by the study's IRB approval. Specific requests can be submitted through the UCSF MAC Resource Request form. Following a UCSF-regulated procedure, access will be granted to designated individuals in line with ethical guidelines on the reuse of sensitive data. This would require submission of a Material Transfer Agreement. Commercial use will not be approved.